ArticleOncology letters2025
Propionate metabolism-related genes demonstrate the potential to serve as prognostic and immunotherapeutic markers in osteosarcoma.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Understanding the metabolic processes in osteosarcoma (OS) is key for the development of effective diagnostic and therapeutic modalities. Propionate metabolism has been found to have a crucial role in certain cancers, highlighting its potential relevance in OS. The aim of the present study was to identify novel prognostic indicators for OS based on gene expression profiles and clinical data. Differentially expressed genes (DEGs) in OS and propionate metabolism-associated genes were identified by the analysis of public datasets. Subsequently, functional enrichment analysis was performed and a protein-protein interaction network was constructed. Least absolute shrinkage and selection operato-Cox regression analysis was then conducted to construct a risk model, which was used to establish high- and low-risk patient groups, and the association of the risk model with immune cell infiltration and immunotherapy was assessed. Furthermore, a prognostic nomogram was constructed. In addition, cell assays were conducted to evaluate the influence of prognostic gene knockdown on OS cells. The bioinformatics analysis led to the identification of 18 DEGs associated with propionate metabolism in OS, and the risk score model revealed two prognostic genes, namely 4-aminobutyrate aminotransferase (ABAT) and aldehyde dehydrogenase 7 family member A1 (ALDH7A1). Immune infiltration analysis highlighted a significant difference between high- and low-risk groups, indicating a potential impact on the response to immune therapy. In addition, the propionate metabolism-related gene signatures effectively distinguished OS patients with distinct clinical outcomes and tumor microenvironments, and single-cell analysis revealed associations of ABAT and ALDH7A1 with immune cell infiltration. Furthermore, cell assays revealed that the knockdown of ABAT promoted OS cell growth, migration and invasion. In conclusion, the present study emphasized the relevance of propionate metabolism in OS and introduced a novel gene signature for clinical outcome prediction. Furthermore, the identified genes, ABAT and ALDH7A1, may hold promise as potential therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.